Evidence map›Paper›PMID 40263625›Full record

ReviewEMBO molecular medicine2025

Metabolic reprogramming in polycystic kidney disease and other renal ciliopathies.

Sara Clerici, Alessandra Boletta

Abstract readReview
In one paragraph

Review in EMBO molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sara ClericiDivision of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0002-3911-9944
Alessandra BolettaDivision of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy. boletta.alessandra@hsr.it.ORCID 0000-0002-4704-4006

Funding

EC | ERC | HORIZON EUROPE European Research Council (ERC) 101142691-QtCiliaEC | ERC | HORIZON EUROPE European Research Council (ERC) TheRaCiL-101080717Fondazione AIRC per la ricerca sul cancro ETS (AIRC) IG2024-30769
6 · The paper itself

Abstract

Primary cilia are solitary organelles formed by a microtubule-based skeleton protruding in a single copy on the surface of most cells. Alterations in their function cause a plethora of human conditions collectively called the ciliopathies. The kidney is frequently and severely affected in the ciliopathies, presenting with a spectrum of phenotypes. Cyst formation is a common trait of all renal ciliopathies. Besides this common manifestation, however, the renal ciliopathies present with profoundly different phenotypes, resulting in either polycystic kidney disease (PKD) or nephronophthisis (NPH) phenotypes. The past decade has seen a surge of studies highlighting metabolic reprogramming as a major feature of PKD, with a distinct involvement of mitochondrial dysfunction. This discovery has brought forward the development of novel therapeutic approaches. More recent evidence suggests that primary cilia modulate the mitochondrial production of energy in response to environmental cues. Here, we summarize the evidence available to date and propose a more general involvement of metabolic and mitochondrial alterations in the renal ciliopathies that might in principle help defining the profoundly different, and potentially opposite, manifestations observed.

Indexed as

CiliaCiliopathiesPolycystic Kidney DiseasesAnimalsHumansKidneyMetabolic ReprogrammingMitochondriaCiliaCiliopathiesKidney CystsMetabolismMitochondria

Identifiers

PMID40263625
PMCPMC12162851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.